Molecular mechanisms of varicella zoster virus pathogenesis

Nature Reviews Microbiology

Volumn 12, Issue 3, 2014, Pages 197-210

  Zerboni, Leigh ^a   Sen, Nandini ^a   Oliver, Stefan L ^a   Arvin, Ann M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CHICKENPOX; DISEASE MODELS, ANIMAL; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HETEROGRAFTS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MICE, SCID; MUTATION; VIRAL TROPISM;

EID: 84894039546     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3215     Document Type: Review

References (109)

1. Arvin, A. M. & Gilden, D. in Fields Virology 6th Edn (Eds Knipe, D., Howley, P.) 2015-2057 (Lippincott Williams & Wilkins, 2013).
2. Ku, C. C. et al. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-α. J. Exp. Med. 200, 917-925 (2004).
3. Gilden, D. H. et al. Varicella-zoster virus DNA in human sensory ganglia. Nature. 306, 478-480 (1983).
4. Takahashi, M. Clinical overview of varicella vaccine: development and early studies. Pediatrics. 78, 736-741 (1986).
5. Gershon, A. A. & Gershon, M. D. Perspectives on vaccines against varicella-zoster virus infections. Curr. Top. Microbiol. Immunol. 342, 359-372 (2010).
6. Weibel, R. E. et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N. Engl. J. Med. 310, 1409-1415 (1984).
7. Cohen, J. I. The varicella-zoster virus genome. Curr. Top. Microbiol. Immunol. 342, 1-14 (2010).
8. Chen, J. J. et al. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell. 119, 915-926 (2004).
9. Suenaga, T. et al. Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. Proc. Natl Acad. Sci. USA 107, 866-871 (2010).
10. Yang, M., Hay, J. & Ruyechan, W. T. Varicella-zoster virus IE62 protein utilizes the human mediator complex in promoter activation. J. Virol. 82, 12154-12163 (2008).
11. Ruyechan, W. T. Roles of cellular transcription factors in VZV replication. Curr. Top. Microbiol. Immunol. 42, 43-65 (2010).
12. Heineman, T. C. & Cohen, J. I. The varicella-zoster virus (VZV) open reading frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22. J. Virol. 69, 7367-7370 (1995).
13. Moffat, J. F. et al. The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc. Natl Acad. Sci. USA 95, 11969-11974 (1998).
14. Besser, J. et al. Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse. J. Virol. 77, 5964-5974 (2003).
15. Erazo, A. & Kinchington, P. R. Varicella-zoster virus open reading frame 66 protein kinase and its relationship to alphaherpesvirus US3 kinases. Curr. Top. Microbiol. Immunol. 342, 79-98 (2010).
16. Schaap, A. et al. T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J. Virol. 79, 12921-12933 (2005).
17. Schaap-Nutt, A. et al. ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo. J. Virol. 80, 11806-11816 (2006).
18. Eisfeld, A. J. et al. Phosphorylation of the varicella-zoster virus (VZV) major transcriptional regulatory protein IE62 by the VZV open reading frame 66 protein kinase. J. Virol. 80, 1710-1723 (2006).
19. Reichelt, M., Brady, J. & Arvin, A. M. The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J. Virol. 83, 3904-3918 (1999).
20. Grose, C., Carpenter, J. E., Jackson, W. & Duus, K. M. Overview of varicella-zoster virus glycoproteins gC, gH and gL. Curr. Top. Microbiol. Immunol. 342, 113-128 (2010).
21. Maresova, L. et al. Characterization of interaction of gH and gL glycoproteins of varicella-zoster virus: their processing and trafficking. J. Gen. Virol. 81, 1545-1552 (2000).
22. Vleck, S. E. et al. Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model. J. Virol. 84, 141-152 (2010).
23. Vleck, S. E. et al. Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism. Proc. Natl Acad. Sci. USA 108, 18412-18417 (2011).
24. Oliver, S. L. et al. Mutagenesis of varicella-zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. J. Virol. 83, 7495-7506 (2009).
25. Oliver, S. L. et al. An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis. Proc. Natl Acad. Sci. USA 110, 1911-1916 (2013).
26. Moffat, J. F. et al. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J. Virol. 72, 965-974 (1998).
27. Zerboni, L. et al. Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc. Natl Acad. Sci. USA 102, 6490-6495 (2005).
28. Ku, C. C. et al. Tropism of varicella-zoster virus for human tonsillar CD4+ T lymphocytes that express activation, memory and skin homing markers. J. Virol. 76, 11425-11433 (2002).
29. Longnecker, R., Kieff, E. & Cohen, J. in Fields Virology 6th Edn (Eds Knipe, D., Howley, P) 1898-1957 (Lippincott Williams & Wilkins, 2013).
30. Abendroth, A. et al. Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J. Virol. 75, 6183-6192 (2001).
31. Huch, J. H. et al. Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection. J. Virol. 84, 4060-4072 (2010).
32. Sen, N. et al. STAT3 activation and survivin induction by varicella zoster virus promotes viral replication and skin pathogenesis. Proc. Natl Acad. Sci. USA 109, 600-605 (2012).
33. Moffat, J. F. et al. Functions of C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J. Virol. 78, 12406-12415 (2004).
34. Besser, J., Ikoma, M. & Fabel, K. Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection of skin and T cells. J. Virol. 78, 13293-13305 (2004).
35. Koropchak, C. M. et al. Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J. Virol. 63, 2392-2395 (1989).
36. Ozaki, T. et al. Viremic phase in nonimmunocompromised children with varicella. J. Pediatr. 104, 85-87 (1984).
37. Arvin, A. M. et al. Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr. Top. Microbiol. Immunol. 342, 189-209 (2010).
38. Berarducci, B. et al. Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. J. Virol. 83, 228-240 (2009).
39. Berarducci, B. et al. Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc. Natl Acad. Sci. USA 107, 282-287 (2010).
40. Mallory, S., Sommer, M. & Arvin, A. M. Mutational analysis of varicella-zoster virus (VZV) glycoproteins, gI and gE, in recombinant VZV strains. J. Virol. 71, 8279-8288 (1997).
41. Li, Q. et al. Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability. PLoS ONE. 5, e11327 (2010).
42. Moffat, J. F. et al. Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J. Virol. 76, 8468-8471 (2002).
43. Ito, H. et al. Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. J. Virol. 77, 489-498 (2003).
44. Che, X., Zerboni, L., Sommer, M. H. & Arvin, A. M. Varicella-zoster virus open reading frame 10 is a virulence determinant in skin cells but not in T cells in vivo. J. Virol. 80, 3238-3248 (2006).
45. Baiker, A. et al. The immediate-early 63 protein of varicella-zoster virus: analysis of functional domains required for replication in vitro and T cell and skin tropism in the SCIDhu model in vivo. J. Virol.78, 1181-1194 (2004).
46. Kinchington, P. R. et al. Virion association of IE62, the varicella-zoster virus (VZV) major transcriptional regulatory protein, requires expression of the VZV open reading frame 66 protein kinase. J. Virol. 75, 9106-9113 (2001).
47. Eisfeld, A. J., Yee, M. B., Erazo, A., Abendroth, A. & Kinchington, P. R. Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and-independent mechanisms. J. Virol. 81, 9034-9049 (2007).
48. Abendroth, A., Kinchington, P. R. & Slobedman, B. Varicella zoster virus immune evasion strategies. Curr. Top. Microbiol. Immunol. 342, 155-171 (2010).
49. Bontems, S. et al. Phosphorylation of varicella-zoster virus IE63 protein by casein kinase influences its cellular localization and gene regulation activity. J. Biol. Chem. 277, 21050-21060 (2002).
50. Sommer, M. H. et al. Mutational analysis of varicella-zoster virus ORF63/70 and ORF64/69. J. Virol. 75, 8224-8239 (2001).
51. Hoover, S. E. et al. Downregulation of varicella-zoster virus (VZV) immediate-early ORF62 transcription by VZV ORF63 correlates with virus replication in vitro and with latency. J. Virol. 80, 3459-3468 (2006).
52. Zuranski, T. et al. Cell-type-dependent activation of the cellular EF-1α promoter by the varicella-zoster virus IE63 protein. Virology 338, 35-42 (2005).
53. Niizuma, T. et al. Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. J. Virol. 77, 6062-6065 (2003).
54. Peng, H. et al. Interaction between the varicella-zoster virus IE62 major transactivator and cellular transcription factor SP1. J. Biol. Chem. 278, 38068-38075 (2003).
55. Berarducci, B., Sommer, M., Zerboni, L., Rajamani, J. & Arvin, A. M. Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication. J. Virol. 81, 10258-10267 (2007).
56. Jones, J. O. & Arvin, A. M. Inhibition of the NF-κB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J. Virol. 80, 5113-5124 (2006).
57. Arvin, A. M. et al. The early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J. Infect. Dis. 154, 422-429 (1986).
58. Zerboni, L. et al. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology. 332, 337-346 (2005).
59. Schmid, D. S. Varicella-zoster virus vaccine: molecular genetics. Curr. Top. Microbiol. Immunol. 342, 323-340 (2010).
60. Gershon, M. D., Gershon A. A. VZV infection of keratinocytes: production of cell-free infectious virions in vivo. Curr. Top. Microbiol. Immunol. 342, 173-188 (2010).
61. Sen, N. et al. Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J. Virol. 84, 9240-9253 (2010).
62. Vandevenne, P. et al. The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS ONE 6, e16870 (2011).
63. Ambagala, A. P. & Cohen, J. I. Varicella-Zoster virus IE63, a major viral latency protein, is required to inhibit the alpha interferon-induced antiviral response. J. Virol. 81, 7844-7851 (2007).
64. Carpenter, J. E., Jackson, W., Benetti, L. & Grose, C. Autophagosome formation during varicella-zoster virus infection following endoplasmic reticulum stress and the unfolded protein response. J. Virol. 85, 9414-9424 (2011).
65. Reichelt, M. et al. Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog. 7, e1001266 (2011).
66. Reichelt, M. et al. 3D reconstruction of herpesvirus infected cell nuclei and PML nuclear cages by serial section array scanning electron microscopy and electron tomography. PLoS Pathog. 8, e1002740 (2012).
67. Wang, L. et al. Disruption of PML nuclear bodies is mediated by ORF61 sumo-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PloS Pathog. 7, e1002157 (2011).
68. Wang, L., Sommer, M., Rajamani, J. & Arvin, A. M. Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis. J. Virol. 83, 7560-7572 (2009).
69. Breuer, J. VZV molecular epidemiology. Curr. Top. Microbiol. Immunol. 342, 15-42 (2010).
70. Santos, R. A. et al. Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology 275, 306-317 (2000).
71. Oliver, S. L. et al. Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells. J. Virol. 85, 4095-4110 (2011).
72. Sato, B. et al. Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J. Virol. 77, 5607-5620 (2003).
73. Che, X. et al. Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. J. Virol. 82, 5825-5834 (2008).
74. Che, X. et al. ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection. J. Virol. 87, 5106-5117 (2013).
75. Liu, X., Li, Q., Dowdell, K., Fischer, E. R. & Cohen, J. I. Varicella-zoster virus ORF12 protein triggers phosphorylation of ERK1/2 and inhibits apoptosis. J. Virol. 86, 3143-3151 (2012).
76. Liu, X. & Cohen, J. I. Varicella-zoster virus ORF12 protein activates the phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle progression. J. Virol. 87, 1842-1848 (2013).
77. Zhang, Z. et al. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS Pathog. 6, e1000971 (2010).
78. Chaudhuri, V., Sommer, M., Rajamani, J., Zerboni, L. & Arvin, A. M. Functions of varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection. J. Virol. 82, 10231-10246 (2008).
79. Pevenstein, S. R. et al. Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J. Virol. 73, 10514-10518 (1999).
80. Wang, K. et al. Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal ganglia at the single cell level. J. Virol. 79, 14079-14087 (2005).
81. Azarkh, Y., Gilden, D. & Cohrs, R. J. Molecular characterization of varicella zoster virus in latently infected human ganglia: physical state and abundance of VZV DNA, quantitation of viral transcripts and detection of VZV-specific proteins. Curr. Top. Microbiol. Immunol. 342, 229-241 (2010).
82. Nagel, M. A. et al. Varicella-zoster virus transcriptome in latently infected human ganglia. J. Virol. 85, 2276-2287 (2011).
83. Mahalingam, R. et al. Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons. Proc. Natl Acad. Sci. USA 93, 2122-2124 (1996).
84. Lungu, O. et al. Aberrant intracellular localization of varicella-zoster virus regulatory proteins during latency. Proc. Natl Acad. Sci. USA 95, 7080-7085 (1998).
85. Zerboni, L. et al. Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group A determinants in sensory neurons. J. Virol. 86, 578-583 (2012).
86. Gowrishankar, K. et al. Characterization of the host immune response in human ganglia after herpes zoster. J. Virol. 84, 8861-8870 (2010).
87. Steain, M., Gowrishankar, K., Rodriguez, M., Slobedman, B. & Abendroth, A. Upregulation of CXCL10 in human dorsal root ganglia during experimental and natural varicella-zoster virus infection. J. Virol. 85, 626-631 (2011).
88. Steain, M., Slobedman, B. & Abendroth, A. Experimental models to study varicella-zoster virus infection of neurons. Curr. Top. Microbiol. Immunol. 342, 211-228 (2010).
89. Hood, C. et al. Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J. Virol. 80, 1025-1031 (2006).
90. Janer, A. et al. PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins. J. Cell Biol. 174, 65-76 (2006).
91. Weinberg, A. et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200, 1068-1077 (2009).
92. Reichelt, M., Zerboni, L. & Arvin, A. M. Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J. Virol. 82, 3971-3983 (2008).
93. Zerboni, L. et al. Herpes simplex virus 1 tropism for human sensory ganglion neurons in the severe combined immunodeficiency mouse model of neuropathogenesis. J. Virol. 87, 2791-2802 (2013).
94. Esiri, M. M. & Tomlinson, A. H. Herpes zoster: demonstration of virus in trigeminal nerve and ganglion by immunofluorescence and electron microscopy. J. Neurol. Sci. 15, 35-48 (1972).
95. Zerboni, L. et al. Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis. J. Virol. 85, 98-111 (2011).
96. Zerboni, L., Reichelt, M. & Arvin, A. Varicella-zoster virus neurotropism in SCID mouse-human dorsal root ganglia xenografts. Curr. Top. Microbiol. Immunol. 342, 255-276 (2010).
97. Zerboni, L. et al. Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I. Proc. Natl Acad. Sci. USA 104, 14086-14091 (2007).
98. Wang, Z. H. et al. Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. J. Virol. 75, 323-340 (2001).
99. Mahalingam, R., Messaoudi, I. & Gilden, D. Simian varicella virus pathogenesis. Curr. Top. Microbiol. Immunol. 342, 309-321 (2010).
100. Ouwendijk, W. J. et al. T-cell infiltration correlates with CXCL10 expression in ganglia of cynomolgus macaques with reactivated simian varicella virus. J. Virol. 87, 2979-2982 (2013).
101. Kinchington, P. R. & Goins, W. F. Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. J. Neurovirol. 17, 590-599 (2011).
102. Chen, J. J., Gershon, A. A., Li, Z., Cowles, R. A. & Gershon, M. D. Varicella zoster virus (VZV) infects and establishes latency in enteric neurons. J. Neurovirol.17, 578-589 (2011).
103. Selariu, A. et al. ORF7 of varicella-zoster virus is a neurotropic factor. J. Virol. 86, 8614-8624 (2012).
104. Oxman, M. N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352, 2271-2284 (2005).
105. Pahud, B. A., Glaser, C. A., Dekker, C. L., Arvin, A. M. & Schmid, D. S. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J. Infect. Dis. 203, 316-323 (2011).
106. Tyring, S. et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann. Intern. Med. 123, 89-96 (1995).
107. Cohen, J. I. & Seidel, K. E. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. Proc. Natl Acad. Sci. USA 90, 7376-7380 (1993).
108. Tischer, B. K. et al. A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J. Virol. 81, 13200-13208 (2007).
109. Rowe, J., Greenblatt, R. J., Liu, D. & Moffat, J. F. Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice. Antiviral Res. 86, 276-285 (2010).